[Frontiers in Bioscience E2, 1015-1027, June 1, 2010]
A new method of screening human papillomavirus genotypes and clinical validation
Peng-jun Zhang1, Xin-xin Deng1, Gan-rong Bai2, Shu-fang Jiang3, Cui-lian Lu4, Xue-ji Zhang1, Hong-li Tong1, Ye-nong Du1, Hua-yang Fu2, Peng Huang2, Ying Ma3, Ya-ping Tian1
1Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, China, 2Research Center of Science and Technology Application of Genome, City University of Hongkong, Hongkong, China, 3Department of gynaecology and obstetrics, Chinese PLA General Hospital, Beijing, China, 4Beijing Aerospace Central Hospital, Beijing, China
TABLE OF CONTENTS
Human papillomavirus (HPV) infection is a necessary factor in the development of cervical cancer. A new HPV screening method, "Human Papillomavirus Genotyping (HPG)", was developed to detect 29 HPV genotypes distribution in China. The utility of HPG was compared to Hybrid Capture 2 High-Risk HPV DNA test (HC2), and it was determined that the HPG test had been proven to be a more credible and sensitive screening HPV method than the HC2 test. HPV16, HPV 52, HPV 56, and HPV 58 were the four most common HPV genotypes in women who have suffered chronic cervicitis or abnormal vaginal bleeding in China. HPV 16 (28.57%) and 18 (17.86%) were more likely to infect multiple HPV genotypes than other HPV genotypes. Age group more than 50 years had a higher risk than other age groups.